amv564
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 20, 2017 (NCT03144245)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Myeloid cell surface antigen CD33INHIBITOR
CD33 inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS56FUB33G5M ↗
- ChEMBLCHEMBL4297552 ↗
Also known as
- amv564
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04128423 | Phase 1 | Oct 9, 2019 | Affimed GmbH |
| NCT03516591 | Phase 1 | Jun 22, 2018 | Affimed GmbH |
| NCT03144245 | Phase 1 | Mar 20, 2017 | Affimed GmbH |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affimed GmbH | For profit | 3 | 3 | 1 | 2017 |
1 organizations
Page 1 / 1